Analyst consensus rating
Indivior Pharmaceuticals Analyst Rating: Strong Buy
INDV is rated Strong Buy by 4 analysts with a $49.00 target. As of 2026-08-22.
Direct answer
Indivior Pharmaceuticals's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $49.00.
Forecast evidence checked August 22, 2026.
Get free Indivior Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $36.87
- Average price target
- $49.00
- High price target
- $53.00
- Low price target
- $43.00
- Low target gap
- +16.6%
- Target upside
- +32.9%
- High target gap
- +43.7%
- Target range width
- 27.1%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Indivior Pharmaceuticals?
Indivior Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $49.00.
How far are Indivior Pharmaceuticals's low and high targets from the recorded price?
The low target implies +16.6%, while the high target implies +43.7%.
How many analysts are included in Indivior Pharmaceuticals's consensus?
The verified consensus includes 4 analysts.
How is Indivior Pharmaceuticals's target upside or downside calculated?
The average target of $49.00 is divided by the recorded price of $36.87, then one is subtracted to produce +32.9%. This does not guarantee a future return.
When was Indivior Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.